pharma · Non-small Cell Lung Cancer · Epilepsy
Eisai
Eisai Co.,
Eisai clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Tokyo, Japan, JP
- Employees
- 41
- Programs
- 22
- Drugs
- 31
- Patents
- 0
Eisai projects
11 ClinicalTrials.gov programs sponsored by Eisai.
Eisai has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BB-1701-G000-205
Eisai Co.,
HER2 positive or HER2-low metastatic breast cancer
1 trial -
E2007-G000-236
Eisai Co.,
Childhood Epilepsy
1 trial -
E7080
Eisai Co.,
Solid Tumors
1 trial -
E7090
Eisai Co.,
Cholangiocarcinoma
1 trial -
E7386-G000-201
Eisai Co.,
colorectal cancer, melanoma, hepatocellular carcinoma
1 trial -
E7386-J081-102
Eisai Co.,
Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor
1 trial -
FOLFIRI
Eisai Co.,
Colon Cancer
1 trial -
Lenvatinib
Eisai Co.,
Osteosarcoma
1 trial -
MORAb-202-G000-201
Eisai Co.,
Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).
1 trial -
Tazemetostat
Eisai Co.,
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
1 trial -
eribulin mesylate + erlotinib
Eisai Co.,
Non-small Cell Lung Cancer
1 trial
Frequently asked questions
How many clinical projects does Eisai have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.